Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
Primary Industries
- Drugs
- Vaccine
- Therapeutic
- Disease
- Delivery
- Pharmaceuticals
- Cancer
- Biotechnology
- Drug Discovery
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 4244
License Grant
The Licensor entered into a License Agreement with the Korean Licensee, to develop, manufacture and commercialize influenza vaccines using the Licensee's proprietary VLP technology.
License Property
The Licensor is a clinical-stage biopharmaceutical company focused on developing novel and effective recombinant vaccines. These vaccines leverage the Licensor's platform technology coupled with a single-use bioprocessing production system to develop virus-like particle (VLP) vaccines, as well as recombinant nanoparticle vaccines.
VLPs are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Company’s VLPs resemble the virus they were engineered to mimic, but lack the genetic material to replicate the virus and its single-use bioprocessing production technology uses insect cells rather than chicken eggs or mammalian cells.
The Licensor’s current product targets include VLP vaccines against seasonal and pandemic (including H5N1) influenza and a recombinant nanoparticle vaccine against Respiratory Syncytial Virus (RSV).
The upfront payment has been deferred and will be recognized as revenue when certain obligations in the agreement are satisfied.
Field of Use
At its own cost, the Licensee is responsible for funding its clinical development of the influenza VLP vaccines and completing a manufacturing facility in South Korea.
IPSCIO Record ID: 371191
License Grant
The Company holds an exclusive, worldwide license from the Licensor, a British university technology transfer and consultancy company, to certain specified patent rights and biological materials relating to the use of epitopes of limited variability and virus-like particle products and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for influenza. The Company is obligated to use its best efforts to develop and market Licensed Products in accordance with its development plan.
License Property
The patent, United States Patent No. 11,123,442, includes claims directed to specific compositions of polypeptides, or epitopes of limited variability, and methods of treating influenza infection with the compositions.
Epitopes or protein of antigens which can be utilized to develop singular or multi-targeted vaccines. Epitopes can simply be fused to the end of the S domain via flexible linker through recombinant DNA technology. Identified epitopes of limited variability in H1 influenza that have circulated throughout history (since 1918) and make ideal vaccine targets and have completed similar analysis of H3 and Flu B strains for similar epitopes which will be used to produce our lead vaccine candidate BWV-101 as a universal vaccine for influenza infection. Due to the cross-reactive nature of the H1 epitopes in pre-pandemic H1 influenza A, companies are pursuing the development of a stand-alone H1 vaccine (BWV-102). These epitopes are able to be formulated into a vaccine candidate using the VLP platform technologies and may be evaluated using other vaccine technologies through partnerships in order to accelerate development of potential vaccines or to explore adjunct therapies.
Field of Use
The Company is currently developing a universal influenza vaccine and an H1N1 vaccine candidate that both utilize the epitopes of limited variability that are covered in the patent.
Field of use is for the treatment of influenza.
IPSCIO Record ID: 253954
License Grant
The Parties agree to jointly research and develop Candidate Antigens and Licensed Products under a research program in accordance with the initial research plan.
For the Licenses for Collaboration Patents the Australian Licensors grants a nonexclusive, worldwide license, with the right to sublicense, under any Collaboration Patents that are owned solely by Licensor.
For the License for Licensed Products the Licensor grants to an exclusive license under the Licensed Subject Matter to develop, make, have made, use, offer to sell, sell, have sold and import Licensed Products within the Licensed Territory for use within the Licensed Field.
License Property
Licensed Product means a Vaccine Product that is covered by or made using Licensed Subject Matter and contains a Target Antigen related to a Target Disease.
Virus-like particles (VLPs) in their second-generation application are constructs that can be engineered to carry foreign antigens on their surface and mimic viruses in their ability to stimulate strong immune responses, in this case against foreign antigens.
Field of Use
The agreement is to collaborate in the discovery and development of vaccines against certain disease targets. The Licensed Field means the development and commercialization of Vaccine Products for human therapeutic and prophylactic use.
The research and development (R&D) partnership focused on the use of Select Vaccines’ virus-like particles (VLPs) as a platform technology for the development of viral vaccines. The R&D efforts will initially target the development of vaccines against influenza including both epidemic and pandemic forms of vaccine, with the opportunity to expand the collaboration to other disease targets.
IPSCIO Record ID: 4747
License Grant
This is an exclusive License to use a proprietary cell line to develop and potentially commercialize recombinant human papillomavirus (HPV) virus-like particle (VLP) vaccines.
Pursuant to the License Agreement, Licensee has an exclusive worldwide License to develop, manufacture and market HPV-16 VLP vaccines for the prevention and/or treatment of HPV infection, except that Licensor retained the right to co-market the product in the United States, including Puerto Rico.
Field of Use
The parties are currently working together on manufacturing HPV-16 VLP vaccines being evaluated by the National Cancer Institute in clinical trials. The vaccines are designed to prevent and/or treat HPV-16 infection and associated cervical cancer.
IPSCIO Record ID: 8916
License Grant
A pharma company purchased another pharma from its parent company.
License Property
The main technologies being acquired are a proprietary vaccine delivery platform (Virosome), as well as intranasal influenza and respiratory synctial virus (RSV) vaccines and Herpes Simplex virus (HSV) vaccine development.
Field of Use
The field of use relates to the medical industry.
IPSCIO Record ID: 27993
License Grant
The Company hereby grants the exclusive right and license in, to, and under the Novavax IP in the Field within the Territory. The exclusive license shall be for the period in which any Novavax IP or patents covering the Joint Improvement(s) shall remain valid and enforceable, unless earlier terminated as provided.
License Property
The Licensor has certain proprietary know-how in the field of encapsulated drug delivery systems and has developed certain proprietary adjuvants, such as a Novasome® delivery system; and the Licensee has certain proprietary know-how in the field of vaccines and has developed and continues to develop proprietary vaccines, especially a vaccine comprising antigenic determinants of an influenza virus.
The parties desire for Licensee to develop, manufacture, market, distribute and sell a product for treating or preventing influenza virus and/or infection, such as a vaccine comprising antigenic determinants of an influenza virus, like Fluogen®, which includes a proprietary adjuvant developed by Licensor.
Field of Use
Field shall mean (a) the use of Novavax IP in any manner whatsoever to develop, create, invent, manufacture, promote, market, offer-for-sale, sell, import and/or export an Influenza Product involved in or concerned with the treatment or prevention of influenza virus or any other purpose for which an Influenza Product may be indicated, and (b) the subsequent exploitation of an Influenza Product in the territory.
IPSCIO Record ID: 299287
License Grant
Licensor grants to the Licensee of Korea an exclusive right and license in the Field under the Licensor Patent Rights, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale Licensor Licensed Products in the Territory only.
License Property
Licensor has a universal influenza vaccine delivered with electroporation, SynCon â„¢ Universal influenza DNA vaccine in conjunction with electroporation.
The patents include Improved vaccines and methods for using the same; Novel vaccines against multiple subtypes of influenza virus; Influenza Nucleic acid molecules and vaccines made therefrom; and, Nucleic acid molecule encoding concensus influenza a hemagglutinin H!
SynCon™ technology enables the design of “universal†DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens such as influenza.
Field of Use
Field means a limitation on the application or utilization of Patent Rights to the field of DNA based vaccines against influenza that are delivered to a subject using electroporation, and its use to treat or protect a subject by delivering to such subject along with electroporation.
IPSCIO Record ID: 253968
License Grant
University grants an exclusive, worldwide license, with the right to sublicense through multiple tiers, under the Patent Rights to develop, make, have made, use, and sell Licensed Products in the Field.
License Property
The licensed property includes any patents and patent applications that cover inventions disclosed in University invention disclosure UMMC05-46 entitled Virus-Like Particles as Vaccines for Paramyxovirus, including without limitation those applications having serial numbers 60/706,126; 11/497,888, and PCT filing.
Field of Use
Field means the diagnosis, prevention and/or treatment of any diseases and conditions in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
